

## Recombinant Cynomolgus PD-L1 (C-Fc)

Catalog No: CA94

<b>Description</b>	Recombinant Cynomolgus CD274 molecule is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a Fc tag at the C-terminus.
<b>Expression System</b>	Human Cells
<b>Alternative name</b>	B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1
<b>Accession No.</b>	G7PSE7
<b>Mol Mass</b>	52.4kDa
<b>AP Mol Mass</b>	73kDa, reducing conditions
<b>Quality Control</b>	Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
<b>Reconstitution</b>	It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
<b>Storage</b>	Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
<b>Background</b>	CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

### SDS-PAGE

